1
|
Volkova Y, Scherbakov A, Dzichenka Y, Komkov A, Bogdanov F, Salnikova D, Dmitrenok A, Sachanka A, Sorokin D, Zavarzin I. Design and synthesis of phosphoryl-substituted steroidal pyridazines (Pho-STPYRs) as potent estrogen receptor alpha inhibitors: targeted treatment of hormone-dependent breast cancer cells. RSC Med Chem 2024; 15:2380-2399. [PMID: 39026643 PMCID: PMC11253874 DOI: 10.1039/d4md00153b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2024] [Accepted: 05/30/2024] [Indexed: 07/20/2024] Open
Abstract
Estrogen receptor alpha (ERα) is an important target for the discovery of new therapeutic drugs against hormone-dependent breast cancer. A series of phosphoryl-substituted steroidal pyridazines (Pho-STPYRs) were synthesized and biologically evaluated as potent ERα inhibitors. Pho-STPYRs showed cytotoxicity against breast cancer cells with IC50 values of 5.9 μM and higher. Pho-STPYRs 33 and 34 [IC50 (MCF7) = 6.5 and 5.9 μM, respectively] were found to block the expression of ERα, the main driver of breast cancer growth, and modulate the ERK, cyclin D1, and CDK4 pathways. Compound 34 showed selectivity, anti-estrogenic potency and high antiproliferative efficacy in combination with the AKT inhibitor. Molecular docking was used to more accurately define the binding mode of lead compounds 33 and 34 to ERα. The selectivity analysis showed that lead compounds 33 and 34 produce no effects on cytochromes P450, including CYP7A1, CYP7B1, CYP17A1, CYP19A1, and CYP21A2. In a word, Pho-STPYRs 33 and 34 are promising ERα inhibitors for the treatment of hormone-dependent breast cancer.
Collapse
Affiliation(s)
- Yulia Volkova
- N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences 47 Leninsky prosp 119991 Moscow Russia
| | - Alexander Scherbakov
- Department of Experimental Tumor Biology, N. N. Blokhin National Medical Research Center of Oncology 24 Kashirskoe shosse 115522 Moscow Russia
- Gause Institute of New Antibiotics 11 Bol'shaya Pirogovskaya ulitsa 119021 Moscow Russia
| | - Yaraslau Dzichenka
- Institute of Bioorganic Chemistry, National Academy of Sciences of Belarus 5/2 Kuprevich Str 220141 Minsk Belarus
| | - Alexander Komkov
- N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences 47 Leninsky prosp 119991 Moscow Russia
| | - Fedor Bogdanov
- Department of Experimental Tumor Biology, N. N. Blokhin National Medical Research Center of Oncology 24 Kashirskoe shosse 115522 Moscow Russia
- Faculty of Medicine, Moscow State University 27-1 Lomonosovsky prosp 119192 Moscow Russia
| | - Diana Salnikova
- N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences 47 Leninsky prosp 119991 Moscow Russia
- Department of Experimental Tumor Biology, N. N. Blokhin National Medical Research Center of Oncology 24 Kashirskoe shosse 115522 Moscow Russia
| | - Andrey Dmitrenok
- N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences 47 Leninsky prosp 119991 Moscow Russia
| | - Antos Sachanka
- Institute of Bioorganic Chemistry, National Academy of Sciences of Belarus 5/2 Kuprevich Str 220141 Minsk Belarus
| | - Danila Sorokin
- Department of Experimental Tumor Biology, N. N. Blokhin National Medical Research Center of Oncology 24 Kashirskoe shosse 115522 Moscow Russia
| | - Igor Zavarzin
- N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences 47 Leninsky prosp 119991 Moscow Russia
| |
Collapse
|
2
|
Birukova V, Scherbakov A, Ilina A, Salnikova D, Andreeva O, Dzichenka Y, Zavarzin I, Volkova Y. Discovery of highly potent proapoptotic antiestrogens in a series of androst-5,16-dienes D-modified with imidazole-annulated pendants. J Steroid Biochem Mol Biol 2023; 231:106309. [PMID: 37037385 DOI: 10.1016/j.jsbmb.2023.106309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/02/2023] [Revised: 03/29/2023] [Accepted: 04/07/2023] [Indexed: 04/12/2023]
Abstract
Heterocyclic derivatives of steroid hormones are potent anticancer agents, which are used in the chemotherapy of breast and prostate cancers. Here, we describe a novel series of androstenes, D-modified with imidazole-annulated pendants, with significant anticancer activity. Novel C17-linked imidazole-annulated heterocyclic derivatives of dehydropregnenolone acetate were synthesized by the cyclocondensation with amidines using 3β-acetoxy-21-bromopregna-5,16-dien-20-one as the substrate. The antiproliferative potency of all the synthesized compounds was evaluated against human prostate (22Rv1) and human breast (MCF7) cancer cell lines and cytochromes P450. The lead compound, imidazo[1,2-a]pyridine derivative 3h, was revealed to be a promising candidate for future anticancer drug design, particularly against ERα-positive breast cancer. Lead compound 3h was found to be selective against MCF7 cells with IC50 of 0.1μM and to act as both a potent selective agent blocking estrogen receptor α, which is involved in the stimulation of breast cancer growth, and an effective apoptosis inducer. The potential ability of compound 3h to bind to ERα was studded using molecular docking and molecular dynamics simulation. The selectivity analysis showed that lead steroid 3h produces no effects on cytochromes P450 CYP17A1, CYP7A1, and CYP21A2.
Collapse
Affiliation(s)
- Valentina Birukova
- N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 47 Leninsky prosp., 119991 Moscow, Russia
| | - Alexander Scherbakov
- Department of Experimental Tumor Biology, N. N. Blokhin National Medical Research Center of Oncology, 24 Kashirskoe shosse, 115522 Moscow, Russia
| | - Anastasia Ilina
- N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 47 Leninsky prosp., 119991 Moscow, Russia
| | - Diana Salnikova
- Department of Experimental Tumor Biology, N. N. Blokhin National Medical Research Center of Oncology, 24 Kashirskoe shosse, 115522 Moscow, Russia
| | - Olga Andreeva
- Department of Experimental Tumor Biology, N. N. Blokhin National Medical Research Center of Oncology, 24 Kashirskoe shosse, 115522 Moscow, Russia
| | - Yaraslau Dzichenka
- Institute of Bioorganic Chemistry, National Academy of Sciences of Belarus, 5/2 Kuprevich str., 220141, Minsk, Belarus
| | - Igor Zavarzin
- N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 47 Leninsky prosp., 119991 Moscow, Russia
| | - Yulia Volkova
- N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 47 Leninsky prosp., 119991 Moscow, Russia
| |
Collapse
|
3
|
Gagliano-Jucá T, Hirsch MS, McGregor BA, Basaria S. Failure of Androgen-Deprivation Therapy Due to Ectopic hCG Secretion. N Engl J Med 2023; 388:660-662. [PMID: 36791169 DOI: 10.1056/nejmc2213461] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
|